Brazil’s diabetes medication market is one of the most important and active parts of the country’s healthcare system. It serves more than 16 million adults with diabetes, making Brazil one of the top five countries in the world for diabetes prevalence. The market is expected to grow at a compound annual growth rate of 4.10% through 2033, reaching a value of about USD 1.66 billion in 2025. This is because more people are becoming obese, the population is getting older and healthcare is becoming more accessible.
Brazil’s diabetes drug market is different because it has a unique dual structure. Global multinationals bring cutting-edge innovation and new therapies, while powerful domestic companies use their knowledge of local manufacturing, flexible regulations and strong ties with Brazilian healthcare providers to gain a large share of the market. The government’s Unified Health System (SUS) is very important because it makes sure that people who don’t have a lot of money can afford diabetes medications and provides subsidized access to them. ANVISA’s rules that are good for business have sped up drug approvals and led to partnerships with global pharmaceutical companies. Recent patent expirations, such as the March 2026 expiration of Ozempic’s patent, are changing the way companies compete and giving domestic manufacturers new chances they have never had before.
This carefully chosen list includes five well-known companies that make diabetes medications in Brazil. They were chosen because they are leaders in their field, have a strong product portfolio, can come up with new ideas and help with diabetes care all over the country. This overview gives useful information about Brazil’s diabetes drug market, whether you are a healthcare professional, an investor, or an industry analyst.
How We Selected the Top Diabetes Medication Companies in Brazil
We evaluated the companies included in this list using the following general criteria:
- Market Leadership: Market share position and revenue generation in Brazil’s diabetes medication sector
- List of Products Strength: Presence in important diabetes drug classes like insulins, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors and oral combinations.
- Innovation Capacity: Putting money into research and development, new treatments and better ways to deliver them
- Manufacturing and Distribution Network: Can reach patients all over Brazil’s continental area
- Regulatory Compliance: A history of meeting ANVISA standards and keeping the supply chain safe
List of Top 5 Diabetes Medication Companies in Brazil
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi Aventis SA
- EMS
- Hypera Pharma
A Closer Look at Each Diabetes Medication Company
1. Novo Nordisk A/S
Novo Nordisk is the clear world leader in diabetes care and has a strong presence in Brazil. The Danish pharmaceutical giant has built its reputation on a century of specializing in diabetes. It has a full range of products, including insulins, GLP-1 receptor agonists (medications that stimulate insulin secretion) and oral antidiabetic agents (drugs taken by mouth to help control blood sugar levels).
Key Products Offered
- Ozempic® (semaglutide) for type 2 diabetes is a GLP-1 receptor agonist that reached R$. 3.1 billion dollars in sales each year in Brazil—the most money ever made by a single drug in the country
- Insulins: A full range of insulins, including Levemir®, NovoRapid® and human insulins, to meet the needs of all diabetes patients.
- Oral antidiabetic agents: a portfolio that goes well with injectable therapies
- Wegovy® (semaglutide) is a weight-loss drug that works for more than just diabetes.
Ideal Client Type
Patients with type 1 and type 2 diabetes across all stages of disease progression and healthcare providers seeking comprehensive, science-backed treatment options with proven efficacy.
Notable Strengths or Differentiators
Novo Nordisk’s deep knowledge of diabetes gives them an edge in clinical excellence. Ozempic, the company’s drug, has become a cultural and commercial phenomenon in Brazil, making billions of dollars a year and changing the way diabetes and obesity are treated. Novo Nordisk has shown its commitment to Brazil by investing R$6.4 billion to expand its manufacturing facility in Montes Claros, Minas Gerais, even though its patent will expire in March 2026. This will strengthen its long-term presence and industrial capacity in the country.
The company’s innovation pipeline keeps coming up with new therapies that are better than the ones that are already on the market, which keeps it ahead of the competition even as generic drugs become available, particularly in the areas of diabetes and obesity treatment where they have established a strong foothold. Novo Nordisk will be able to stay on top of the changing Brazilian market because it has both global research and development resources and local manufacturing investment.
Contact Information
Website: www.novonordisk.com.br
2. Eli Lilly and Company
Eli Lilly is a major player in Brazil’s diabetes medication market and is known around the world for its innovative diabetes care. With the approval and launch of next-generation therapies that compete with established market leaders, such as Mounjaro® (tirzepatide), the company has gained a lot of momentum in the Brazilian diabetes medication market.
Key Products Offered
- ANVISA approved Mounjaro® (tirzepatide) for type 2 diabetes in September 2023. It works in two ways, making it a new type of drug.
- Insulins: a full range of products, including Humalog® and Humulin®
- Oral Antidiabetic Agents: Well-known products that help people with diabetes manage their condition
- Pipeline Innovations: A candidate for oral GLP-1, orforglipron, is moving closer to submitting to the government
Ideal Client Type
Patients seeking the latest therapeutic innovations; those with type 2 diabetes requiring advanced glucose control and weight management benefits; and healthcare providers adopting novel treatment paradigms.
Notable Strengths or Differentiators
Eli Lilly’s tirzepatide (Mounjaro) is a big step forward in treatment because it works better than other GLP-1 agonists at both controlling blood sugar and helping people lose weight. With this new product, Lilly is now a direct competitor to Novo Nordisk, which has been the leader in the incretin class. A patent in Brazil protects the company’s tirzepatide until 2035, providing ample time for market expansion.
Lilly’s aggressive growth in Brazil is part of its global plan to become the leader in diabetes and obesity. The company’s stock has done better in 2025, as it has gained ground on its competitors, particularly due to the successful launch of tirzepatide and increased market share in diabetes and obesity treatments. Its pipeline, which includes oral formulations and next-generation molecules, makes sure it stays relevant in the changing therapeutic landscape by addressing the evolving needs of patients and healthcare providers in diabetes and obesity treatment.
Contact Information
Website: www.lilly.com.br
3. Sanofi Aventis SA
Sanofi Aventis is a major player in Brazil’s diabetes drug market. They have been around for decades and have a strong portfolio of insulin therapies. The company is always one of the best in the Brazilian diabetes drug market.
Key Products Offered
- Insulins: A wide range, including Lantus® (insulin glargine), a long-acting insulin that is the best-selling in its class and Apidra® (insulin glulisine). Insulins: A wide range, including Lantus® (insulin glargine), a long-acting insulin that is the best-selling in its class and Apidra® (insulin glulisine).
- Oral Antidiabetic Agents: A portfolio that works with insulin therapies Oral Antidiabetic Agents: A portfolio that works with insulin therapies
- Diabetes Management Solutions: Integrated strategies that merge pharmacological treatments with patient assistance initiatives, including education on lifestyle changes and regular monitoring of blood glucose levels. Diabetes Management Solutions: Integrated strategies that merge pharmacological treatments with patient assistance initiatives, including education on lifestyle changes and regular monitoring of blood glucose levels.
Ideal Client Type
Patients with type 1 and type 2 diabetes require reliable insulin therapy, while healthcare providers seek trusted, established brands with proven safety and efficacy.
Notable Strengths or Differentiators
Sanofi’s strength comes from its knowledge of insulin and the trust it has built up over decades in Brazilian healthcare. Lantus® has been a mainstay of basal insulin therapy and endocrinologists all over the country trust and prescribe it. The company’s manufacturing and distribution infrastructure makes sure that Brazil’s vast territory gets a steady supply, reaching patients in both cities and rural areas.
Sanofi is one of the big multinational companies that shape Brazil’s diabetes market, which is beneficial for the company. Its knowledge of regulations and connections with ANVISA make it easier to get products approved and manage their life cycles, which ultimately helps Sanofi maintain a competitive edge and ensure a steady supply of essential diabetes medications to patients. Sanofi’s insulin portfolio is still crucial for millions of Brazilian patients, even though it faces competition from biosimilars and newer drug classes. This feature keeps the company relevant in the market.
Contact Information
Website: www.sanofi.com.br
4. EMS
EMS is Brazil’s biggest pharmaceutical company and a major player in the diabetes medication market, especially because it has been very aggressive in the generic and similar drug segments. The company has put itself at the front of the race to make a generic version of Ozempic by spending a lot of money to take advantage of this multibillion-real opportunity.
Key Products Offered
- Olire® and Lirux® (liraglutide similars), which are GLP-1 analogs, came out in 2025 at prices that were about 15% lower than those of branded competitors.
- Semaglutide Generics: Products in the pipeline that are ready to be released as soon as the patent runs out in March 2026
- Insulin biosimilars: Adding to the list of biologic diabetes treatments
- Oral Antidiabetic Generics: A full range that includes all major drug classes
Ideal Client Type
Price-sensitive patients seeking affordable access to essential diabetes therapies, public healthcare system (SUS) purchasers and private pharmacy chains seeking high-margin generic alternatives.
Notable Strengths or Differentiators
EMS has shown unparalleled aggressiveness in pursuing the semaglutide opportunity. The company spent more than R$1 billion on its manufacturing plant in Hortolândia, São Paulo, where it can now make everything from active pharmaceutical ingredients to finished products. This vertical integration makes sure that costs are kept in check and supplies are always available, which are significant benefits in the competitive generic market.
The company’s early mover advantage in liraglutide similars (Olire and Lirux) has given them useful experience in dealing with ANVISA’s rules for complicated biologic generics, which positions them well to navigate regulatory challenges as they expand into new markets, including the potential entry into the US market. EMS has already talked to the FDA about possibly entering the US market, which shows that it wants to do business around the world. EMS projects that its GLP-1 line could bring in up to US$4 billion a year, split between Brazil and international markets. This is because it can make products for both domestic and export markets, which allows EMS to capitalize on the growing demand for GLP-1 medications globally.
Contact Information
Website: www.ems.com.br
5. Hypera Pharma
Hypera Pharma, which used to be called Hypermarcas, is the biggest pharmaceutical company in Brazil and a major player in the diabetes medication market. Hypera is in charge of the trusted Neo Química brand, which means that millions of Brazilians can get cheap, high-quality medicines.
Key Products Offered
- GLP-1 Analogs: Semaglutide generics in development, positioned for ANVISA registration and launch post-patent expiration
- Oral Antidiabetic Portfolio: A full range of generic oral drugs from all major classes
- Diabetes adjunctive therapies: products that help with diabetes-related problems and other diseases
- Neo Química Brand: Affordable diabetes medications reaching price-sensitive consumers
Ideal Client Type
The ideal client type includes mass-market consumers seeking affordable diabetes treatments, patients familiar with and trusting the Neo Qumica brand and pharmacy chains seeking reliable generic suppliers.
Notable Strengths or Differentiators
Hypera’s biggest strengths are its huge distribution network and its deep understanding of Brazilian consumers. One of the most well-known pharmaceutical brands in the country is Neo Química. People trust it because it is high quality and cheap. This brand equity gives diabetes generics a strong base to start from because patients and pharmacists already trust the company.
The company’s large-scale manufacturing operations let them keep quality standards high while keeping prices low. Hypera’s knowledge of ANVISA (the Brazilian Health Regulatory Agency) rules and its long-standing connections with pharmacy chains across Brazil will help it quickly enter the market. penetration for new products. As the semaglutide market opens to generic competition, Hypera is well-positioned to capture significant share through its brand recognition, distribution strength and manufacturing capability.
Contact Information
Website: www.hyperapharma.com.br
How to Choose the Right Diabetes Medication Company in Brazil
- Therapeutic Class Specialization: Different companies lead in different drug classes. Novo Nordisk dominates GLP-1 and insulin; Eli Lilly advances novel dual agonists; Sanofi leads in basal insulin; and EMS and Hypera excel in generics and similars.
- Balancing Innovation and Access: Companies like Novo Nordisk and Eli Lilly offer cutting-edge new products at high prices, while EMS and Hypera focus on making important medicines affordable through generics and similar products.
- Patent and Regulatory Timeline: The March 2026 expiration of the semaglutide patent will cause a big change in the market. Companies like EMS and Hypera that are good at following rules and making things are in a good position to take advantage of this chance.
- Manufacturing Presence in Brazil: Having factories in Brazil makes sure that supplies are always available and prices are competitive. Novo Nordisk’s R$6.4 billion investment in Montes Claros and EMS’s R$1 billion Hortolândia facility show that they are committed to making things in Brazil.
- Public Sector Reach: Companies that want to win SUS contracts need to have experience with public tenders, be able to offer competitive prices and be able to deliver goods on time.
- Brand Trust and Recognition: Recognition of a brand is important in consumer-facing areas. The growing reputation of EMS as a reliable generic provider and Hypera’s Neo Química brand affect the choices of pharmacies and patients.
Brazil’s diabetes medication market is shaped by a dynamic interplay between global innovation leaders and powerful domestic champions, each bringing distinct strengths to serving the country’s 16 million-plus diabetes patients.
Novo Nordisk A/S is the market leader and innovator. Ozempic has broken sales records and the company has made a long-term commitment to Brazil by investing R$6.4 billion in manufacturing. Eli Lilly and Company is the next big thing in innovation. Mounjaro has better effectiveness and a long patent protection period, which means it can keep growing. Sanofi Aventis SA makes the insulin that is needed for diabetes care. They have been in Brazil for decades and have trusted brands, so you can trust them. EMS has become the most aggressive competitor in Brazil, investing more than R$1 billion in manufacturing capacity and having a clear plan to take advantage of the multibillion-real semaglutide opportunity. Hypera Pharma’s Neo Química brand gives it a huge advantage in brand recognition and distribution, which puts it in a good position to get a big share of the next wave of generic drugs.
The end of Ozempic’s patent in March 2026 will change the way Brazil treats diabetes, as it will allow for the introduction of more affordable generic alternatives, potentially increasing access to treatment for a larger population. The market for injectable diabetes and weight-loss drugs is currently worth R$11 billion a year. By 2026, it is expected to be worth about R$20 billion, thanks to the entry of generic drugs, lower prices and more people being able to get them. Domestic companies like EMS, Hypera, Cimed, Biomm and others are trying to take advantage of this chance to expand their market share and develop affordable alternatives, while multinationals like Novo Nordisk and Eli Lilly protect their positions by coming up with new ideas, investing in manufacturing and making products that are part of the next generation pipeline.
For patients, this competition means more access to life-changing treatments that most Brazilians can’t get right now. Only 2.5% of obese adults in Brazil can currently get semaglutide-based treatments. In the next few years, healthcare providers will have access to a wider range of treatment options than ever before, at a range of prices. Brazil is one of the most dynamic diabetes markets in the world for investors and industry stakeholders. Growth is driven by changing epidemiological trends, changing regulations and more competition, which together create opportunities for innovative treatments and improved patient outcomes in diabetes care.
We encourage readers to monitor this rapidly evolving sector closely, as the companies profiled here will continue to shape the future of diabetes care in Brazil.
FAQ
1. What is the current size of Brazil’s diabetes medication market?
The market for diabetes drugs in Brazil was worth about USD 1.66 billion in 2025 and is expected to grow at a rate of 4.10% per year until 2033. The injectable diabetes and obesity segment alone makes about R$11 billion a year right now.
2. Which companies lead the diabetes medication market in Brazil?
A mix of international and domestic companies leads the market. Novo Nordisk, Eli Lilly and Sanofi are some of the biggest companies in the world. At home, EMS and Hypera Pharma are quickly gaining market share, especially in the generic and similar segments.
3. What is the significance of the Ozempic patent expiration in March 2026?
The patent for Ozempic runs out on March 20, 2026, which means that Brazil will be able to sell generic and similar versions of semaglutide. This should lower prices by a lot, make it easier for more people to get care and create a multibillion-real opportunity for manufacturers in Brazil. By 2026, the market could be worth about R$20 billion, or twice as much.
4. Which Brazilian companies are preparing to launch generic semaglutide?
Others, like EMS, Hypera Pharma, Cimed, Biomm (in partnership with Indian Biocon) and others, are getting ready for the market after patents expire. EMS has spent more than R$1 billion on manufacturing and released liraglutide-like products in 2025 as a test run.
5. What are the main types of diabetes medications available in Brazil?
In Brazil, you can buy insulins (basal, bolus, human and biosimilar), oral anti-diabetic drugs (biguanides, DPP-4 inhibitors, SGLT-2 inhibitors and sulfonylureas), non-insulin injectables (GLP-1 receptor agonists) and combination therapies.
6. How does Brazil’s public health system (SUS) affect the diabetes medication market?
SUS helps people who can’t afford diabetes medications by making them cheaper and creating a lot of demand in the public sector. This role of the government affects how the market works and how prices are set.
7. What role does ANVISA play in diabetes medication regulation?
The National Health Surveillance Agency (ANVISA) is in charge of all parts of diabetes medications, such as approving clinical trials, giving permission to market them, keeping an eye on their production and keeping an eye on them after they are sold. Its rules and timelines for entry into the market have a big effect on how businesses compete.
8. What are the newest innovations in diabetes treatment available in Brazil?
Recent innovations include Eli Lilly’s Mounjaro® (tirzepatide), which is a dual GLP-1/GIP receptor agonist that was approved in 2023 and works better than other drugs. Oral GLP-1 candidates and next-generation molecules are being developed, which means that therapeutic progress will continue.
9. Where are diabetes medications typically purchased in Brazil?
You can get diabetes medications from retail pharmacies, hospital pharmacies and more and more online pharmacies. Retail pharmacies are the most common way to get medications and major chains make them easy to find.
10. What is the future outlook for Brazil’s diabetes medication market?
The market outlook is strongly positive, driven by rising diabetes prevalence, an aging population, increasing healthcare access and continuous therapeutic innovation. The entry of generic GLP-1 products starting in 2026 will dramatically expand access, potentially transforming diabetes and obesity treatment in Brazil.
